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Background: This study was performed to estimate the annual direct cost incurred by 
dry eye patients, which includes expenses for treatment and drugs, as well as the cost of 
  punctal plugs.
Methods: The study group consisted of 118 dry eye patients aged 20 years or older who visited 
any of the 15 medical care facilities that participated in this prospective cohort dry eye study. 
We estimated annual direct costs from outpatient medical records and survey questionnaires 
obtained from patients.
Results: Of the total patients enrolled, 10 were men and 108 women, and their average age was 
64.1 ± 11.2 years. The number of hospital visits made by patients was 5.8 ± 3.6 per year. Among 
those who used ophthalmic solutions, the numbers of bottles used per year were as follows: 
32.1 ± 20.8 bottles of hyaluronic acid ophthalmic solution (87 patients), 53.1 ± 42.2 bottles of 
artificial tears (40 patients), and 33.2 ± 23.2 bottles of over-the-counter eyedrops (15 patients). 
In patients with punctal plugs, 4.1 ± 3.9 plugs were used annually. The annual drug cost was 
32,000 ± 21,675 Japanese yen (323 ± 219 US dollars). The clinical cost was 16,318 ± 9961 
Japanese yen (165 ± 101 US dollars). The total direct costs including punctal plug treatment 
amounted to 52,467 ± 38,052 Japanese yen (530 ± 384 US dollars).
Conclusion: Although treatment modalities for dry eye in Japan were different from those in 
the US and in European countries, the direct cost of dry eye patients in Japan was comparable 
with that reported in those countries. Considering the high prevalence of dry eye, the direct cost 
of this chronic condition may be significant.
Keywords: burden of disease, cost, dry eye, eyedrops, quality of life
Introduction
Dry eye is recognized as a common eye disease with a high prevalence in many 
countries, including Japan.1,2 Although dry eye rarely leads to blindness or visual 
impairment, the condition exerts a key influence on quality of life (QOL) and imposes 
a burden on patients.3–5 Miljanovic et al reported that patients with dry eye syndrome 
have more difficulty in reading, performing professional work, using a computer, 
watching television, and driving, as compared with those without dry eye.6 Utility 
assessment is a formal method for quantifying the relative impact of a given health state 
or disease on patient lives, which is defined on a continuous scale from 0 to 1, where 
0 corresponds to the worst possible QOL weight (equal to death) and 1   corresponds 
to the best possible QOL weight (equal to perfect health). Schiffman et al reported 
that the mean utility score of moderate dry eye was 0.81 and that of severe dry eye 
was 0.72.7 Hence, there appears to be a considerable burden of dry eye disease based 
on both its prevalence and patient morbidity.
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In addition to impairment of QOL, the financial burden 
can be a cause of concern for patients with dry eye.1,8–11 
Financial burden consists of direct costs, including medical 
fees and drug expenses, and indirect costs, including absence 
from work and decreased productivity. Studies to estimate 
the direct and indirect costs of dry eye have been conducted 
in European countries and in the US.1,8–11 The average annual 
direct costs of dry eye have been reported to be 600 US 
dollars in studies from six European countries.8 In addition, 
the indirect financial burden in the form of work absences 
and decreased productivity cannot be overlooked, with 
studies showing that patients with dry eye lose 2–5 working 
days per year and work with the symptoms for more than 
6 months.10,11
Assessing multiple aspects of the burden of this disease 
appears to be important from the perspective of medical 
care assessment or medical economics. The Dry Eye Survey 
Group consisting of 15 facilities, mostly affiliated with the 
National Hospital Organization in Japan, has been conducting 
a multicenter prospective cohort study on dry eye patients 
to investigate the effect of the disease from the patient 
perspective. This article reports the results of analysis on 
the direct costs of dry eye patients in Japan.
Materials and methods
This study was performed as part of a multicenter cohort 
study being conducted at 15 facilities comprising 13 affiliate 
hospitals of the National Hospital Organization, Keio 
University, and Tokyo Dental College (see Appendix). The 
subjects enrolled in the study were dry eye patients aged 
20 years and older who visited any of the facilities. The 
diagnostic criteria used in this study complied with those 
defined by the Japanese Dry Eye Society, with a slight 
modification (Table 1).12 All cases with definite dry eye 
according to the criteria were enrolled in the study. The 
principles of the World Medical Association Declaration of 
Helsinki were followed. Each subject was given a thorough 
explanation of the purpose of the study and all procedures 
involved, and the subjects provided written informed consent 
prior to enrollment. Approval for this research was granted 
by the Committee for the Protection of Human Subjects at 
each hospital.
The cases were registered between April 2005 and March 
2008, with a total of 158 cases being initially registered. For 
the registered cases, information on ocular findings from 
the responsible physicians was collected. One year after 
registration in the cohort study, clinical data were collected 
from each facility. Information on drug expenses and number 
of hospital visits was also collected from the patients through 
a survey questionnaire. For this particular report, we analyzed 
the prescribed drugs and number of hospital visits in one year 
based on clinical data and patient questionnaire data collected 
during registration and one year later. Twelve patients were 
excluded because clinical data at one year after registration 
could not be obtained from the facilities. Twenty-eight 
patients were excluded because the survey questionnaire at 
one year was not returned. Consequently, we used the data 
from 118 subjects for analysis.
All medical costs are uniformly standardized by the 
social medical insurance system in Japan. Medical costs 
associated with dry eye were calculated based on the Japanese 
Social Insurance Medical Fee Payment for 2008. Based 
on hospital visits in one year, doctor fees were calculated 
assuming that an examination, slit-lamp biomicroscopy, 
and vital staining for corneal and conjunctival epithelium 
were performed at each hospital visit, and that a Schirmer’s 
test, intraocular pressure measurement, and corrected vision 
testing were performed once a year. Costs for punctal plugs 
were calculated from the data based on the number of punctal 
plugs inserted. Drug costs were the one-year total of the 
basic preparation charges, charges for issuing prescriptions, 
and drug costs. The ophthalmic solutions focused on were 
hyaluronic acid eyedrops, artificial tears, chondroitin sulfate 
eyedrops, steroid eyedrops, nonsteroidal anti-inflammatory 
drug eyedrops, and antimicrobial eyedrops and ointments. In 
the case of patients using over-the-counter eyedrops, numbers 
of units and expenses were calculated approximately from 
questionnaires because the details could not be found in 
outpatient medical records. The direct cost consists of the 
medical and drug costs, and the expenses of plug insertion.
Results
The age of the 118 patients (10 men, 108 women) enrolled 
in the study ranged from 33 to 84 years with an average of 
Table 1 Diagnosis criteria for dry eye for this study
Having subjective symptoms due to dry eye
Abnormality in tear function
  1. Schirmer’s I testing (without anesthesia) ,5 mm
  2. Tear film break-up time ,5 seconds
    Positive when either of 1 or 2 is applicable
Abnormality in corneal and conjunctival epithelium
  1. Fluorescein staining score (range 0–9) .3
  2. Rose bengal staining score (range 0–9) .3
    Positive when either of 1 or 2 is applicable
Notes: The criteria primarily complied with those defined by Japanese Dry Eye 
Society  with  a  slight  modification.12  Definite  dry  eye  was  diagnosed  when  all 
conditions were met.
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64.1 ± 11.2 years. Of these 118 patients, 47 had Sjögren’s 
syndrome. Accordingly, some patients with Sjögren’s 
syndrome visited the internal medicine department and the 
ophthalmology department on the same day. There were no 
ocular comorbidities, such as glaucoma and retinal disorders, 
which might affect the frequency of hospital visits. Results 
of clinical tests for dry eye at the time of enrollment and one 
year later are shown in Table 2. There were no statistically 
significant differences in the results of clinical tests 
between enrollment and one year later (P . 0.05, Mann-
Whitney test).
The annual number of hospital visits made by the 118 
patients in the study was 5.8 ± 3.6 (range 1–19). With regard 
to treatment modalities, hyaluronic acid ophthalmic solutions 
were used by 73.7% of patients, artificial tears in by 33.9% 
of patients, antimicrobials by 15.3% of patients, steroids 
by 18.6% of patients, nonsteroidal anti-inflammatory drugs 
by 7.6% of patients, chondroitin sulfate eyedrops by 9.3% 
of patients, and over-the-counter eyedrops by 12.7% of 
patients (Table 3). Punctal plugs were used by 11 patients 
(9.3%), whereas there were no cases treated with other 
surgical procedures, such as surgical punctal occlusion 
or tarsorrhaphy. Among those who used the respective 
ophthalmic solutions, the numbers of bottles used per year 
were as follows: 32.1 ± 20.8 bottles of hyaluronic acid 
ophthalmic solution (87 patients), 53.1 ± 42.2 bottles of 
artificial tears (40 patients), and 33.2 ± 23.2 of over-the-
counter eyedrops (15 patients). In patients with punctal plugs, 
4.1 ± 3.9 plugs were used annually.
From these data, the annual clinical cost was estimated 
to be 16,318 ± 9961 Japanese yen (165 ± 101 US dollars, 
calculated based on the yen-US dollar exchange rate in 
March, 2008, Table 4). The pharmacological cost was 
32,000 ± 21,675 Japanese yen (323 ± 219 US dollars) per year, 
and the cost of punctal plugs was 4149 ± 17,876 Japanese yen 
(42 ± 181 US dollars). The mean annual cost per patient was 
52,467 ± 38,052 Japanese yen (530 ± 384 US dollars).
Discussion
In the current study, the annual direct costs for dry eye in 
Japan were estimated to be 52,467 Japanese yen (530 US 
dollars), which included clinical costs of 16,318 Japanese yen 
(165 US dollars), pharmacological costs of 32,000 Japanese 
yen (323 US dollars), and costs of punctal plugs of 4149 
Japanese yen (42 US dollars). It should be noted that treatment 
modalities for dry eye in Japan are different from those in the 
US and in European countries. Topical immunosuppressants, 
such as cyclosporine, and oral medications have not been 
approved for clinical use in the treatment of dry eye in Japan. 
Instead, hyaluronic acid eyedrops and artificial tears have 
been used as the major treatment modalities for dry eye. As 
shown in Table 3, other treatment modalities, such as steroid 
eyedrops, over-the-counter eyedrops, and punctual plugs, 
were concurrently used in some cases. Recently, two new 
topical agents for treating dry eye, diquafosol tetrasodium 
3% and rebamipide 2%, have been approved for clinical use 
in Japan. These new drugs may alter the preferred practice 
patterns for the treatment of dry eye, but were not approved 
at the time of this study.
Clegg et al reported the results of the annual cost of dry 
eye patients in six European countries by using statistical 
data and interviews (Table 5).8 Although there was a marked 
difference between the lowest amount of 273 US dollars in  Table 2 Characteristics of patients with dry eye in the survey
At  
enrollment
One year   
later
Results of clinical tests (worse eye; n = 118)
Schirmer’s testing (mm) 3.7 ± 2.8 4.4 ± 3.5
Tear film break-up time (sec) 3.7 ± 1.7 3.8 ± 1.6
Fluorescein staining score (range 0–9) 1.9 ± 1.6 2.1 ± 1.7
Rose bengal staining score (range 0–9) 2.0 ± 2.0 2.0 ± 1.9
Notes: Results are expressed as the mean ± standard deviation. There were no 
statistically significant differences in results of clinical tests between enrollment and 
one year later (P . 0.05, Mann-Whitney test).
Table 4 Direct costs for dry eye per year in the survey (Japanese 
yen)
Types of costs Annual costs (mean ± SD, range)
Clinical costs 16,318 ± 9961 (range 2864–53,084)
Drug costs 32,000 ± 21,675 (range 4816–135,944)
Costs for punctal plugs 4149 ± 17,876 (range 0–152,320)
Mean direct cost per patient 52,467 ± 38,052 (range 7680–294,858)
Abbreviation: SD, standard deviation.
Table 3 Treatment modalities for dry eye patients in the survey
Number of  
users (%)
Units used  
annually in users
Ophthalmic solutions
  Hyaluronic acid 87 (73.7%) 32.1 ± 20.8
  Artificial tears 40 (33.9%) 53.1 ± 42.2
  Antimicrobial drops 18 (15.3%) 13.8 ± 18.3
  Steroidal drops 22 (18.6%) 18.4 ± 16.5
  NSAID drops 9 (7.6%) 13.9 ± 9.0
  Chondroitin sulfate 11 (9.3%) 26.3 ± 17.5
  OTC eyedrops 15 (12.7%) 33.2 ± 23.2
Punctal plugs 11 (9.3%) 4.1 ± 3.9
Note: Numbers of units used for treatment are expressed as the mean ± standard 
deviation. 
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; OTC, over-the counter.
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Table 5 Annual costs for dry eye in various countries
Country Costs (US$) Reference
France 273 Clegg et al8
Germany 536 Clegg et al8
Italy 645 Clegg et al8
Spain 765 Clegg et al8
Sweden 415 Clegg et al8
UK 1100 Clegg et al8
US 456 Pflugfelder1
US 11–355* Enzenauer et al9
US 221** Reddy et al10
Japan 530 MIZUNO(current study)
Notes: *Drug costs only; **Clinical costs only.
France and the highest amount of 1100 US dollars in the UK, 
the average expense of 622 US dollars was almost the same 
as that estimated in our study. The result in the US reported 
by Pflugfelder of 446 US dollars was also comparable.1 
Enzenauer et al reported that the annual cost in the particular 
case of ophthalmic solutions was 11–355 US dollars, which 
was in the same range as our results, though there is a 
  difference arising from the type of ophthalmic solutions 
used.9 Gayton estimated that 7–10 million Americans spend 
an average of 320 US dollars per year on artificial tears.13 
Reddy et al reported that the average doctor fees per year was 
211 US dollars.10 Although there are differences in preferred 
treatment modalities for dry eye among countries, there is 
no marked difference between the costs in the countries 
compared.
There are possible limitations to our research. In this 
study, 39% of patients had dry eye associated with Sjögren’s 
syndrome. The predominance of females (92%) in the study 
is partly explained by this comorbidity, although dry eye is 
usually more common in women than in men. Further, this 
study was a hospital-based survey rather than a population-
based survey. One of the clinical issues associated with dry 
eye is that many of the patients have not received medical 
management.1,2 Therefore, it should be noted that the subjects 
in the study may not be representatives of the majority of 
patients with dry eye.
There are several studies of other eye diseases that 
indicate a concern about direct financial burden. It was 
reported that the direct costs of glaucoma in stage 4 were 
2464 US dollars in the US, with approximately half of 
that amount spent on drugs.14 Schmier et al reported that 
yearly expenditures for latanoprost and travoprost in the US 
were 1360 US dollars and 1278 US dollars, respectively.15 
The expenses for diabetic retinopathy are 1118 US dollars 
in the US,16 and for age-related macular degeneration are 
7349 Euros in France, 12,445 Euros in Germany, and 
5732 Euros in Spain.17 Expenditures on other eye diseases 
are high in comparison with the direct financial burden of 
dry eye. Drugs for dry eye are comparatively inexpensive 
and surgical remedies are generally not undertaken except 
for punctal plugs. However, when considering the high 
prevalence of this condition, the direct cost of this chronic 
condition may be significant.
Although not examined in this study, the indirect financial 
burden of dry eye is equally important, with 7% of patients 
obliged to change jobs and 11% forced to cut back on their 
working hours.10 The subjective symptoms inherent in the 
disease, including eye discomfort for more than 6 months, 
contribute to the necessity of taking 2–5 days off from work 
in a year. In the present study, we have shown that patients 
with dry eye visit the hospital on average 5.8 times a year. 
When this time is converted into opportunity cost, it turns 
out to be approximately 500 US dollars. Although there are 
differences in indirect financial burden due to economic 
conditions, working conditions, and calculation methods, 
depending on each country, this cost is a cause of concern 
for the patients and cannot be overlooked. The estimation of 
indirect financial burden of dry eye should be investigated 
in the future.
The research method used here does not involve 
an assessment of outcomes and is called cost analysis. 
Moreover, other methods include cost utility analysis using 
utility and quality-adjusted life years, and cost effectiveness 
analysis based on specific outcomes (eg, life years and 
treatment results) and costs. Although cost analysis is easy 
to implement, it has a disadvantage in that it cannot be used 
to determine directly the distribution of medical resources 
and relative effectiveness of a given strategy for a specific 
treatment. Therefore, the burden of disease and treatment 
assessments using cost effectiveness analysis and cost utility 
analysis are topics for future investigation.
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Appendix
The Dry Eye Survey Group of National 
Hospital Organization in Japan
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H Negishi, A Hayashi, Chiba Medical Center, Chiba; 
Terada H Tachikawa, Disaster Medical Center; T   Katsuta, 
K Fujiike, S Hatou, Tokyo Medical Center, Tokyo; Y Yamada, 
Tokyo Hospital, Kiyose; H Hirose, K Toura, Nagoya Medical 
Center, Nagoya; M Yamamoto, N Yoshida, N Kawagoe, 
Kyoto Medical Center, Kyoto; Y Otori, Y Saito, Y Sakamoto, 
Osaka National Hospital, Osaka; T Nakamura, Kure Medical 
Center and Chugoku Cancer Center, Kure; M Kogiso, Zentsuji 
National Hospital, Zentsuji; H Enaida, T Nagatomi, Kyusyu 
Medical Center, Fukuoka; A Takehara, S Kubota, E Niiro, 
Ureshino Medical Center, Ureshino; H Aoki, Kumamoto 
Medical Center, Kumamoto; N Miyamura, H Hayashida, 
Nagasaki Medical Center, Ohmura; M Kaido, M Dogru, 
K Tsubota, Keio University School of Medicine, Tokyo; 
S Den, J Shimazaki, Tokyo Dental College, Chiba; 
M Yamada, Y Mizuno, G Hanazono, K Tsunoda, Y Miyake, 
National Institute of Sensory Organs, Tokyo Medical 
Center, Tokyo.
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